FDA Brief

Warning letters Drugs

FDA warning letter to

Kenil Healthcare Private Limited

High riskIssued Jun 12, 2025Posted Jun 17, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Kenil Healthcare over adulterated drugs from India due to cleaning, packaging, and quality failures.

What happened

FDA inspected Kenil Healthcare’s Gujarat drug manufacturing facility from December 5 to 11, 2024. Investigators found dirty filling rooms and equipment, packaging and labeling without adequate separation or batch records, improperly stored reserve samples, and quality-unit failures including inadequate records and equipment qualification documents completed after FDA requested them. FDA later recommended a recall of all drug products within expiry in the U.S., and the firm initiated the recall on April 24, 2025.

What FDA found

  1. The firm did not adequately clean and maintain filling rooms and tube filling equipment, with mold, dirt, and product buildup observed.

    21 CFR 211.67(a)
  2. Packaging and labeling were done on the floor with multiple products at once and without adequate separation or batch records, and reserve samples were improperly stored.

    21 CFR 211.42(b)
  3. The quality unit did not provide adequate oversight for manufacturing and quality decisions.

    21 CFR 211.22
  4. The quality unit did not ensure process validation for drug product manufacturing.

    21 CFR 211.100(a)
  5. The quality unit did not establish an adequate ongoing stability program or ensure complete batch records and release review.

    21 CFR 211.166(a), 211.188, and 211.192
  6. The quality assurance manager generated and completed equipment qualification documents after FDA requested them, raising data integrity concerns.

    21 CFR 211.100(b)

What FDA wants

FDA tells the firm to correct violations promptly and respond in writing within 15 working days, including independent assessments and CAPA plans for cleaning, packaging, data integrity, and the quality unit, and to engage a qualified CGMP consultant. If corrective actions cannot be completed in that time, the firm must state the reasons and a completion schedule.

Who should pay attention

  • U.S. distributors and pharmacies selling Kenil Healthcare drug products
  • contract manufacturers and packagers with manual packaging or cleaning problems
  • brands sourcing OTC drugs or cosmetics from India

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium